Video

Importance of Molecular Classification

Molecular classification of tumors with assays like CancerTYPE ID can be beneficial for determining the cancer type in patients with unclear or unknown primary cancers, says F. Anthony Greco, MD. Next-generation sequencing can then be performed using the same biopsy. This can help to guide targeted treatment, including in malignancies of the lung, colon, and breast. Understanding the cancer type and applying the appropriate treatment improves patient outcomes, states Greco.

If CancerTYPE ID results show that a patient has a high probability of having lung cancer, this information can help direct clinicians to look for abnormalities that are common in lung cancer, says Suresh S. Ramalingam, MD. Clinicians may then be able to identify actionable mutations in EGFR or ALK from molecular testing. Physicians should understand the importance of molecular testing in cancers, comments Ramalingam, which is particularly valuable during the time of diagnosis in advanced stage disease.

Related Videos
Steven H. Lin, MD, PhD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.